Trodelvy: Premedication
-
Healthcare professionals recommend using the drug Sacituzumab govitecan-hziy to treat patients with unresectable locally advanced or metastatic triple-negative breast cancer and locally advanced or metastatic urothelial cancer. Trodelvy 180 mg vial for single-dose is used for intravenous administration. Before each dose of Trodelvy, premedication for the prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting (CINV) is recommended. Premedicate with antipyretics, H1 and H2 blockers before infusion and corticosteroids may be used for patients with prior infusion reactions. Premedicate with a two or three-drug combination regimen.